Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Edgewise Therapeutics

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities1.60%
Size of stake in company2.60%
Market capitalizationUSD 1.7 bn

Sector

Muscle diseases

Main candidate

EDG-5506 (Sevasemten) and EDG-7500

Main indications

Duchenne muscular dystrophy, Becker muscular dystrophy and hypertrophic cardiomyopathy (HCM) 

About the company

Edgewise Therapeutics is a biotechnology company founded in 2017 and headquartered in Colorado in the US focused on developing new drugs for muscle diseases. The company is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is a significant unmet medical need. Edgewise are developing their drug candidates using small molecules that target myosin to treat rare muscle disorders. The company´s technology measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. Today, the company´s focus is on Duchenne muscular dystrophy, Becker muscular dystrophy and hypertrophic cardiomyopathy (HCM). The company´s lead candidate is EDG-5506 (Sevasemten) is in phase III development for Becker muscular dystrophy and EDG-7500 is in Phase II development for HCM.   

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.